日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

LRRK2 kinase-mediated accumulation of lysosome-associated phospho-Rabs in tauopathies and synucleinopathies.

LRRK2 激酶介导溶酶体相关磷酸化 Rabs 在 tau 蛋白病和突触核蛋白病中的积累。

Buck Silas A, Malankhanova Tuyana, Strader Samuel, Ma Eileen B, Yim Sarah, Pratt Harrison W, Ervin John, Lee Edward B, Wang Shih-Hsiu J, Cohen Todd J, West Andrew B, Sanders Laurie H

Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies.

tau蛋白病中LRRK2相关磷酸化Rab12退行性溶酶体的积累

Buck Silas A, Malankhanova Tuyana, Ma Eileen B, Yim Sarah, Pratt Harrison W, Ervin John, Wang Shih-Hsiu J, Cohen Todd J, West Andrew B, Sanders Laurie H

Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary

处方医生对生物类似药应用及临床药理学潜在作用的看法:研讨会总结

Shubow, Sophie; Sun, Qin; Nguyen Phan, Ai Len; Hammell, Dana C; Kane, Maureen; Lyman, Gary H; Gibofsky, Allan; Lichtenstein, Gary R; Bloomgarden, Zachary; Cross, Raymond K; Yim, Sarah; Polli, James E; Wang, Yow-Ming

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis

生物类似药与原研生物药转换时的安全性结果:系统评价和荟萃分析

Herndon, Thomas M; Ausin, Cristina; Brahme, Nina N; Schrieber, Sarah J; Luo, Michelle; Andrada, Frances C; Kim, Carol; Sun, Wanjie; Zhou, Lingjie; Grosser, Stella; Yim, Sarah; Ricci, M Stacey

Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity

I型干扰素激活MHC I类分子修饰的CD11b+常规树突状细胞,从而促进保护性抗肿瘤CD8+ T细胞免疫。

Ellen Duong ,Tim B Fessenden ,Emi Lutz ,Teresa Dinter ,Leon Yim ,Sarah Blatt ,Arjun Bhutkar ,Karl Dane Wittrup ,Stefani Spranger